PL405774A1 - Method for detecting of high genetically conditioned risk of the prostatic carcinoma - Google Patents

Method for detecting of high genetically conditioned risk of the prostatic carcinoma

Info

Publication number
PL405774A1
PL405774A1 PL40577413A PL40577413A PL405774A1 PL 405774 A1 PL405774 A1 PL 405774A1 PL 40577413 A PL40577413 A PL 40577413A PL 40577413 A PL40577413 A PL 40577413A PL 405774 A1 PL405774 A1 PL 405774A1
Authority
PL
Poland
Prior art keywords
mutation
gene
chek2
detecting
risk
Prior art date
Application number
PL40577413A
Other languages
Polish (pl)
Other versions
PL236138B1 (en
Inventor
Cezary Cybulski
Jan Lubiński
Original Assignee
Pomorski Uniwersytet Medyczny W Szczecinie
Cezary Cybulski
Jan Lubiński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pomorski Uniwersytet Medyczny W Szczecinie, Cezary Cybulski, Jan Lubiński filed Critical Pomorski Uniwersytet Medyczny W Szczecinie
Priority to PL405774A priority Critical patent/PL236138B1/en
Publication of PL405774A1 publication Critical patent/PL405774A1/en
Publication of PL236138B1 publication Critical patent/PL236138B1/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Wynalazek ujawnia sposoby i produkty znajdujące zastosowanie w diagnozowaniu genetycznej predyspozycji do chorób u ludzi i polega na ocenie czy w materiale biologicznym badanej osoby występuje specyficzna zmiana z panelu siedmiu zmian DNA w tym: 1) mutacja 657del5 genu NBS1; 2) mutacja IVS2+1G>A genu CHEK2; 3) mutacja del5395 genu CHEK2; 4) mutacja 1100delC genu CHEK2; 5) mutacja Il157T genu CHEK2; 6) mutacja G84E genu HOXB13; 7) allel A zmiany rs188140481 w regionie 8q24. Wynalazek dotyczy również nowej metody diagnostycznej wykrywającej wysokie ryzyko raka prostaty u mężczyzn w polskiej populacji.The invention discloses methods and products used in the diagnosis of genetic predisposition to human diseases and consists in assessing whether the biological material of the examined person has a specific change from a panel of seven DNA changes including: 1) mutation 657del5 of the NBS1 gene; 2) IVS2 + 1G> A mutation of the CHEK2 gene; 3) del5395 mutation of the CHEK2 gene; 4) mutation 1100delC of the CHEK2 gene; 5) mutation Il157T of the CHEK2 gene; 6) G84E mutation of the HOXB13 gene; 7) allele A rs188140481 change in region 8q24. The invention also relates to a new diagnostic method detecting the high risk of prostate cancer in men in the Polish population.

PL405774A 2013-10-26 2013-10-26 Method for detecting of high genetically conditioned risk of the prostatic carcinoma PL236138B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL405774A PL236138B1 (en) 2013-10-26 2013-10-26 Method for detecting of high genetically conditioned risk of the prostatic carcinoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL405774A PL236138B1 (en) 2013-10-26 2013-10-26 Method for detecting of high genetically conditioned risk of the prostatic carcinoma

Publications (2)

Publication Number Publication Date
PL405774A1 true PL405774A1 (en) 2015-04-27
PL236138B1 PL236138B1 (en) 2020-12-14

Family

ID=52987886

Family Applications (1)

Application Number Title Priority Date Filing Date
PL405774A PL236138B1 (en) 2013-10-26 2013-10-26 Method for detecting of high genetically conditioned risk of the prostatic carcinoma

Country Status (1)

Country Link
PL (1) PL236138B1 (en)

Also Published As

Publication number Publication date
PL236138B1 (en) 2020-12-14

Similar Documents

Publication Publication Date Title
Yates et al. The European society for medical oncology (ESMO) precision medicine glossary
Harland et al. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom
EP4484572A3 (en) Identification and use of circulating nucleic acid tumor markers
MX2009012722A (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment.
EP2663656A1 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
HRP20191182T1 (en) Identification of tumor-protective epitopes for the treatment of cancers
WO2009009752A3 (en) Genetic models for stratification of cancer risk
Warmoes et al. Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer
HK1197085A1 (en) Genetic variants for predicting risk of breast cancer
Elliott et al. How does Tra2β protein regulate tissue-specific RNA splicing?
Gandolfi et al. The extent of whole‐genome copy number alterations predicts aggressive features in primary melanomas
Renhua et al. 165P: Long noncoding RNA LUCAT1 is associated with poor prognosis in human non-small cell lung cancer and affects cell proliferation via regulating p21 and p57 expression
Abreu et al. Methylation status regulates lipoprotein lipase expression in chronic lymphocytic leukemia
Nissar et al. XRCC3 Thr241Met gene polymorphism and risk of colorectal cancer in Kashmir: a case control study
MXPA06014175A (en) Diagnosing or predicting the course of breast cancer.
Emmert et al. Do not underestimate nucleotide excision repair: it predicts not only melanoma risk but also survival outcome
BRPI0608429A2 (en) method and kit for predicting or evaluating the effectiveness of treating a solid tumor in a patient of interest; and method for identifying markers that are prognostic for a solid tumor
PL405774A1 (en) Method for detecting of high genetically conditioned risk of the prostatic carcinoma
CY1115258T1 (en) METHODS AND USES INCLUDING NAV3 GENETIC DERIVATIVES AND DIFFERENT MULTIPLE GENE EXPRESSION
Peplonska et al. TOMM40 and APOE common genetic variants are not Parkinson's disease risk factors
Ahmad et al. Prognostic effect of vascular endothelial growth factor+ 936C/T polymorphism on tumor growth pattern and survival in patients diagnosed with colon carcinoma
PL401271A1 (en) Method and kit for the detection of aggressive prostate cancer with poor prognosis